Literature DB >> 22314530

Microbiological aetiology, epidemiology, and clinical profile of prosthetic joint infections: are current antibiotic prophylaxis guidelines effective?

Trisha N Peel1, Allen C Cheng, Kirsty L Buising, Peter F M Choong.   

Abstract

Prosthetic joint infections remain a major complication of arthroplasty. At present, local and international guidelines recommend cefazolin as a surgical antibiotic prophylaxis at the time of arthroplasty. This retrospective cohort study conducted across 10 hospitals over a 3-year period (January 2006 to December 2008) investigated the epidemiology and microbiological etiology of prosthetic joint infections. There were 163 cases of prosthetic joint infection identified. From a review of the microbiological culture results, methicillin-resistant Staphylococcus aureus (MRSA) and coagulase-negative staphylococci were isolated in 45% of infections. In addition, polymicrobial infections, particularly those involving Gram-negative bacilli and enterococcal species, were common (36%). The majority (88%) of patients received cefazolin as an antibiotic prophylaxis at the time of arthroplasty. In 63% of patients in this cohort, the microorganisms subsequently obtained were not susceptible to the antibiotic prophylaxis administered. The results of this study highlight the importance of ongoing reviews of the local ecology of prosthetic joint infection, demonstrating that the spectrum of pathogens involved is broad. The results should inform empirical antibiotic therapy. This report also provokes discussion about infection control strategies, including changing surgical antibiotic prophylaxis to a combination of glycopeptide and cefazolin, to reduce the incidence of infections due to methicillin-resistant staphylococci.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22314530      PMCID: PMC3346661          DOI: 10.1128/AAC.06246-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

1.  Histological and microbiological findings in non-infected and infected revision arthroplasty tissues. The OSIRIS Collaborative Study Group. Oxford Skeletal Infection Research and Intervention Service.

Authors:  R Pandey; A R Berendt; N A Athanasou
Journal:  Arch Orthop Trauma Surg       Date:  2000       Impact factor: 3.067

Review 2.  Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project.

Authors:  Dale W Bratzler; Peter M Houck
Journal:  Clin Infect Dis       Date:  2004-05-26       Impact factor: 9.079

Review 3.  Prosthetic-joint infections.

Authors:  Werner Zimmerli; Andrej Trampuz; Peter E Ochsner
Journal:  N Engl J Med       Date:  2004-10-14       Impact factor: 91.245

4.  Deep wound sepsis following total hip arthroplasty.

Authors:  R H Fitzgerald; D R Nolan; D M Ilstrup; R E Van Scoy; J A Washington; M B Coventry
Journal:  J Bone Joint Surg Am       Date:  1977-10       Impact factor: 5.284

5.  Vancomycin versus cefazolin prophylaxis for cardiac surgery in the setting of a high prevalence of methicillin-resistant staphylococcal infections.

Authors:  R Finkelstein; G Rabino; T Mashiah; Y Bar-El; Z Adler; V Kertzman; O Cohen; S Milo
Journal:  J Thorac Cardiovasc Surg       Date:  2002-02       Impact factor: 5.209

6.  Two-stage reconstruction of a total hip arthroplasty because of infection.

Authors:  D J McDonald; R H Fitzgerald; D M Ilstrup
Journal:  J Bone Joint Surg Am       Date:  1989-07       Impact factor: 5.284

7.  An economic model for the prevention of MRSA infections after surgery: non-glycopeptide or glycopeptide antibiotic prophylaxis?

Authors:  Rachel A Elliott; Helen L A Weatherly; Neil S Hawkins; Gillian Cranny; Duncan Chambers; Lindsey Myers; Alison Eastwood; Mark J Sculpher
Journal:  Eur J Health Econ       Date:  2009-08-08

8.  Prophylactic cefazolin versus placebo in total hip replacement. Report of a multicentre double-blind randomised trial.

Authors:  C Hill; R Flamant; F Mazas; J Evrard
Journal:  Lancet       Date:  1981-04-11       Impact factor: 79.321

9.  Management of infection associated with total hip arthroplasty according to a treatment algorithm.

Authors:  S G Giulieri; P Graber; P E Ochsner; W Zimmerli
Journal:  Infection       Date:  2004-08       Impact factor: 3.553

10.  Microbiology of infected arthroplasty: implications for empiric peri-operative antibiotics.

Authors:  D Sharma; J Douglas; C Coulter; P Weinrauch; R Crawford
Journal:  J Orthop Surg (Hong Kong)       Date:  2008-12       Impact factor: 1.118

View more
  51 in total

1.  Etiology of Above-knee Amputations in the United States: Is Periprosthetic Joint Infection an Emerging Cause?

Authors:  Jaiben George; Suparna M Navale; Emmanuel M Nageeb; Gannon L Curtis; Alison K Klika; Wael K Barsoum; Michael A Mont; Carlos A Higuera
Journal:  Clin Orthop Relat Res       Date:  2018-10       Impact factor: 4.176

2.  CORR Insights®: Vancomycin Prophylaxis for Total Joint Arthroplasty: Incorrectly Dosed and Has a Higher Rate of Periprosthetic Infection Than Cefazolin.

Authors:  Alex Soriano
Journal:  Clin Orthop Relat Res       Date:  2017-04-18       Impact factor: 4.176

3.  Trends in orthopaedic antimicrobial prophylaxis in the UK between 2005 and 2011.

Authors:  R S Aujla; D J Bryson; A Gulihar; G J Taylor
Journal:  Ann R Coll Surg Engl       Date:  2013-10       Impact factor: 1.891

4.  Cefuroxime Prophylaxis in Total Joint Arthroplasty: Need for Antibiotic Stewardship.

Authors:  Sujeesh Sebastian; Benu Dhawan; Rajesh Malhotra; Deepak Gautam; Arti Kapil
Journal:  J Clin Diagn Res       Date:  2016-08-01

5.  Prophylaxis with teicoplanin and cefuroxime reduces the rate of prosthetic joint infection after primary arthroplasty.

Authors:  Eduard Tornero; Sebastian García-Ramiro; Juan C Martínez-Pastor; Guillem Bori; Jordi Bosch; Laura Morata; Marta Sala; Misericordia Basora; Josep Mensa; Alex Soriano
Journal:  Antimicrob Agents Chemother       Date:  2014-11-17       Impact factor: 5.191

6.  Staphylococcus aureus Aggregates on Orthopedic Materials under Varying Levels of Shear Stress.

Authors:  Tripti Thapa Gupta; Niraj K Gupta; Matthew J Pestrak; Devendra H Dusane; Janette M Harro; Alexander R Horswill; Paul Stoodley
Journal:  Appl Environ Microbiol       Date:  2020-09-17       Impact factor: 4.792

Review 7.  Coagulase-negative staphylococci.

Authors:  Karsten Becker; Christine Heilmann; Georg Peters
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

8.  Improving surgical antibiotic prophylaxis adherence and reducing hospital readmissions: a bundle of interventions including health information technologies.

Authors:  Almudena Ribed; Beatriz Monje; Xandra García-González; Mar Sanchez-Somolinos; Pablo Sanz-Ruiz; Carmen Guadalupe Rodríguez-González; María Sanjurjo-Saez
Journal:  Eur J Hosp Pharm       Date:  2018-11-26

9.  Prosthetic joint infections.

Authors:  Saima Aslam; Rabih O Darouiche
Journal:  Curr Infect Dis Rep       Date:  2012-10       Impact factor: 3.725

10.  Pathogenic potential of Escherichia coli clinical strains from orthopedic implant infections towards human osteoblastic cells.

Authors:  Lise Crémet; Alexis Broquet; Bénédicte Brulin; Cédric Jacqueline; Sandie Dauvergne; Régis Brion; Karim Asehnoune; Stéphane Corvec; Dominique Heymann; Nathalie Caroff
Journal:  Pathog Dis       Date:  2015-09-01       Impact factor: 3.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.